Who Paid My Doc
Kevin Lorentsen
Hematology & Oncology Chambersburg, PA Medical Doctor
NPI 1700878683 CMS profile 1265240
22 St Paul Dr Ste 100, Chambersburg, PA 17201
General payments
$340
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Kevin Lorentsen of Chambersburg, PA is reported in the CMS Open Payments database as having received $340 across 20 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 22nd percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $84 | 1 | |
| 2021 | General | $12 | 1 | |
| 2020 | General | $14 | 1 | |
| 2019 | General | $230 | 17 |
Beside peers
- Kevin Lorentsen
- Hematology & Oncology median
- Middle half of Hematology & Oncology
- National median
In program year 2025, general payments to Kevin Lorentsen were reported at $0. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.
Show as a table
| Year | Kevin Lorentsen | Hematology & Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $230 | $529 | $121–$2,516 | $163 |
| 2020 | $14 | $339 | $82–$2,213 | $114 |
| 2021 | $12 | $263 | $49–$1,965 | $132 |
| 2022 | $0 | $416 | $103–$2,395 | $149 |
| 2023 | $84 | $542 | $125–$2,646 | $160 |
| 2024 | $0 | $692 | $141–$3,008 | $164 |
| 2025 | $0 | $683 | $143–$3,154 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 35 drugsPart D claims
1,244
Drug cost
$4,537,960
Branded share of claims
31.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Pomalyst Pomalidomide | Brand | 41 | $931,320 | |
| Brukinsa Zanubrutinib | Brand | 47 | $697,581 | |
| Lenalidomide | Generic | 34 | $489,675 | |
| Revlimid Lenalidomide | Brand | 21 | $452,923 | |
| Tagrisso Osimertinib Mesylate | Brand | 19 | $320,879 | |
| Vonjo Pacritinib Citrate | Brand | 12 | $292,564 | |
| Lenvima Lenvatinib Mesylate | Brand | 11 | $263,505 | |
| Jakafi Ruxolitinib Phosphate | Brand | 11 | $235,497 | |
| Lonsurf Trifluridine/Tipiracil Hcl | Brand | 11 | $216,042 | |
| Xtandi Enzalutamide | Brand | 19 | $191,424 |
The 10 drugs with the highest cost, of 35 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 113 billing codesPaid by Medicare
$2,456,479
Medicare patients
533
Services billed
188,356
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Cancer | 46% | |
| Chronic kidney disease | 41% | |
| Diabetes | 39% | |
| Arthritis | 39% | |
| Ischemic heart disease | 31% | |
| Heart failure | 25% | |
| Atrial fibrillation | 24% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, pembrolizumab, 1 mg J9271 | Office | 14 | 12,400 | $551,492 |
| Injection, denosumab, 1 mg J0897 | Office | 29 | 6,120 | $125,637 |
| Injection, epoetin alfa, biosimilar, (retacrit) (for non-esrd use), 1000 units Q5106 | Office | 16 | 4,790 | $27,781 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) Q0138 | Office | 28 | 21,420 | $5,786 |
| Injection, iron sucrose, 1 mg J1756 | Office | 12 | 6,600 | $1,179 |
| Injection, zoledronic acid, 1 mg J3489 | Office | 12 | 72 | $371 |
| Injection, palonosetron hcl, 25 mcg J2469 | Office | 26 | 510 | $357 |
| Injection, paclitaxel, 1 mg J9267 | Office | 13 | 4,095 | $332 |
| Injection, fosaprepitant, 1 mg J1453 | Office | 12 | 2,400 | $265 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 52 | 1,858 | $168 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
20 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hematology & Oncology in Pennsylvania
Salman Fazal
Hematology & Oncology · Pittsburgh, PA
Cyrus Khan
Hematology & Oncology · Pittsburgh, PA
Usama Gergis
Hematology & Oncology · Allentown, PA
Kit Lu
Hematology & Oncology · Harrisburg, PA
Henry Fung
Hematology & Oncology · Philadelphia, PA
Alexander Barsouk
Hematology & Oncology · Pittsburgh, PA
Related records
Hematology & Oncology in Pennsylvania
Practitioners in the same specialty and state, ranked by reported value.
All Hematology & Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Pennsylvania
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.